ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy

NCT ID: NCT03712293

Last Updated: 2024-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-28
• Study Completion Date: 2023-12-31

Brief Summary

The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2.0 used as a tool to disrupt the BBB in patients with Glioblastoma undergoing standard of care therapy.

Detailed Description

This is a prospective, multisingle-center, single-arm study to establish the safety and feasibility of BBB disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2.0 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment. This study will enroll up to 20 subjects.

Conditions

Glioblastoma Multiforme

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BBB Disruption with Chemotherapy Arm

All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).

Group Type: EXPERIMENTAL

BBB Disruption with Chemotherapy Arm

Intervention Type: DEVICE

The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.

Interventions

BBB Disruption with Chemotherapy Arm

The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Patient is eligible for adjuvant TMZ treatment based on the current standard of care.

2. Men or women.

3. Age between 19 and 80 years, inclusive.

4. Able and willing to give informed consent.

5. Grade IV glioma (GBM) confirmed through assessment of surgical specimens by a board-certified neuropathologist.

6. Combined radiation/TMZ treatment is completed based on the prescribed standard of care regimen.

7. Karnofsky rating 70-100 (See Appendix B).

8. Able to communicate during the ExAblate BBBD procedure.

9. Able to attend all study visits (i.e., life expectancy of at least 3 months).

Exclusion Criteria

1. The sonication pathway to the tumor involves:

i. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.

ii. Clips or other metallic implanted objects in the skull or the brain, except shunts.

2. The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).

3. Patients with cerebellar or brainstem tumors.

4. Patient receiving bevacizumab (Avastin) therapy.

5. Patients receiving treatment with corticosteroid doses greater than dexamethasone 16mg daily (or equivalent).

6. Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, focal irradiation with brachytherapy, stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment fields therapy. These regimens have been shown to cause contrast enhancement in the resection cavity boundary, which can be difficult to differentiate from true tumor recurrence [35] [36], [37-39].

7. Cardiac disease or unstable hemodynamics including:

i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.

8. Severe hypertension (diastolic BP > 100 on medication).

9. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment).

10. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.

11. Cerebral or systemic vasculopathy.

12. Evidence of new focal neurological deficits including, but not limited to, motor weakness or speech impairment within 7-14 days prior to the first BBBD procedure.

13. History of drug or alcohol use disorder.

14. Active seizure disorder or epilepsy (seizures despite medical treatment).

15. Known sensitivity to gadolinium-based contrast agents.

16. Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.

17. Contraindications to MRI such as non-MRI-compatible implanted devices.

18. Large subjects not fitting comfortably into the MRI scanner.

19. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.

20. Positive pregnancy test (women of childbearing potential).

21. Severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 and/or on dialysis.

22. Right to left or bi-directional cardiac shunt.

23. Subjects with evidence of cranial or systemic infection.

24. Subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation, or QT prolongation observed on screening ECG (QTc > 450 for men and >470 for women).

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InSightec

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Bernstein

Role: STUDY_DIRECTOR

InSightec

Locations

Severance Hospital, Yonsei University Health System

Seoul, Seodaemun-gu, South Korea

Countries

South Korea

References

Park SH, Kim MJ, Jung HH, Chang WS, Choi HS, Rachmilevitch I, Zadicario E, Chang JW. One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Front Oncol. 2020 Sep 10;10:1663. doi: 10.3389/fonc.2020.01663. eCollection 2020.

Reference Type: DERIVED

PMID: 33014832 (View on PubMed)

Park SH, Kim MJ, Jung HH, Chang WS, Choi HS, Rachmilevitch I, Zadicario E, Chang JW. Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy. J Neurosurg. 2020 Jan 3;134(2):475-483. doi: 10.3171/2019.10.JNS192206. Print 2021 Feb 1.

Reference Type: DERIVED

PMID: 31899873 (View on PubMed)

Other Identifiers

BT008K

Identifier Type: -

Identifier Source: org_study_id